A new study from the University of South Florida College of Nursing found that cannabidiol (CBD) and cannabinol (CBN) show stronger evidence for improving sleep than THC, challenging assumptions that have shaped the cannabis sleep aid market.
"We found that the strongest evidence for improving sleep was associated with cannabidiol (CBD), cannabinol (CBN) and combinations of the two—but not primarily THC," said Andrea Efre, a researcher at USF's College of Nursing.
The findings arrive as the cannabis sleep market expands rapidly, with consumers increasingly seeking natural alternatives to prescription sleep medications. But the research suggests many products may be emphasizing the wrong cannabinoid.
The Market Reality
Cannabis companies have historically marketed THC-dominant products for sleep, banking on the compound's sedative reputation. The new data indicates this approach may miss the mark.
CBD has gained mainstream acceptance for anxiety and pain relief, but its sleep benefits have received less attention in product formulations. CBN, meanwhile, remains relatively obscure despite emerging as a key player in the study's results.
The research reviewed existing scientific literature on cannabinoids and sleep quality, synthesizing evidence across multiple studies. The team specifically examined how different cannabinoids and their combinations affected sleep outcomes.
Industry Implications
The sleep aid category represents one of cannabis's fastest-growing segments. Consumers report insomnia and poor sleep quality as primary reasons for trying cannabis products, second only to pain management.
Yet product shelves tell a different story. Walk into most dispensaries and sleep formulations lean heavily on indica strains and high-THC tinctures. CBD-CBN combinations remain harder to find, and many budtenders lack training on minor cannabinoids.
Some companies have started pivoting. Several brands now offer CBN-specific products, often combined with CBD and marketed at premium prices. But these remain niche compared to THC sleep aids.
What the Science Says
The study adds to a growing body of research examining cannabinoids beyond THC. While THC can induce drowsiness, it may disrupt REM sleep cycles and lead to tolerance issues with regular use.
CBD appears to work differently, potentially addressing underlying causes of poor sleep like anxiety without the psychoactive effects. CBN, often called the "sleepy cannabinoid," forms as THC ages and shows promise as a sedative.
The combination of CBD and CBN may offer synergistic benefits, though researchers note more clinical trials are needed. Most existing studies rely on self-reported outcomes rather than controlled laboratory settings.
What's Next
The research team emphasized the need for rigorous clinical trials examining specific cannabinoid ratios and dosing protocols. Current products vary wildly in formulation, making it difficult for consumers to replicate results.
Regulatory hurdles have slowed cannabis sleep research. Federal restrictions limit access to diverse cannabinoid profiles for study, forcing researchers to work with limited compound variations.
As cannabis rescheduling discussions continue, researchers hope expanded access will enable more comprehensive sleep studies. The USF team plans additional research examining how different cannabinoid combinations affect various sleep disorders.
For now, the findings suggest consumers seeking cannabis sleep aids should look beyond THC content. The future of cannabis sleep products may lie in minor cannabinoids that have spent years in THC's shadow.
This article is based on original reporting by www.marijuanamoment.net.
